Welcome to the portfolio of Advanced Innovative Partners, a biotech pharma company that specializes in developing innovative diagnostic and theranostic for various diseases, including oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures. We are a team of dedicated researchers, clinicians, and engineers who are passionate about harnessing the power of science and technology to tackle some of the world's most pressing health challenges. Through our portfolio, we aim to showcase our expertise and experience in developing cutting-edge solutions that make a difference in the lives of patients and healthcare providers.
Integrins play a critical role in angiogenesis, the physiological process through which new blood vessels from pre-existing ones during embryonic vasculogenesis a vital process in normal organ growth and development.
It is also a fundamental step in the transition of tumors from benign to malignant and represents an effective target to overcome angiogenesis. Integrins are expressed on endothelial cells and mediate cell adhesion, migration, and survival. AIP's anti integrin antagonist is a 'best in class' diagnostic and therapeutic approach for cancer and other angiogenesis-related dieses.
Recent studies demonstrate a link between integrins and PD-L1 expression in
cancer and have been found to be associated with the expression of a protein
that inhibits T cell activation and can prevent immune-mediated destruction of
cancer cells. Integrins can regulate the expression of this protein in breast
cancer cells. Inhibition has been shown to reduce the expression of this protein,
which in turn enhances T cell-mediated killing of cancer cells.
The oncology portfolio includes a range of theranostics that enable precise diagnosis and treatment of various of cancers. The technology improves patient outcomes by providing earlier
and more accurate detection of diseases and enables treatment.
Our radiopharmaceuticals are also used in therapeutic applications, including targeted radionuclide therapy (TRT). These treatments employ radiopharmaceuticals that are designed to selectively deliver radiation to cancerous cells or diseased tissues while minimizing damage to healthy cells. By leveraging the unique properties of radioactive isotopes, our therapies can effectively destroy tumors or manage certain medical conditions with reduced side effects compared to traditional treatments helping patients suffering from breast, lung cancer and other solid tumors.
The rare pediatric disease portfolio includes diagnostic drugs for clinical management addressing a range of rare and debilitating childhood conditions designed to enable earlier and more accurate diagnosis, as well as personalized treatment options for several types of cancers and diseases.
AIP has several orphan diseases for clinical management of Atypical Teratoid Rhabdoid Tumors (AT/RT), Acute Lymphoblastic Leukemia (ALL), Diffuse Intrinsic Pontine Glioma, Hepatoblastoma, Medulloblastoma and several other disease indications. The challenges associated with rare diseases are numerous. Due to their rarity, many rare diseases often go undiagnosed or are misdiagnosed, leading to delays in appropriate treatment and care.
Moreover, limited scientific understanding of these conditions, coupled with a lack of research funding, hinders the development of effective therapies and treatment options. Our objective with developing orphan drugs for clinical management will provide comprehensive information about various rare diseases, including their symptoms, diagnostic methods, available treatments, and ongoing research efforts.
AIP’s infectious disease portfolio includes diagnostic and therapeutic technologies that enable rapid and accurate diagnosis of various infectious diseases, particularly important for sepsis in the context of emerging infectious diseases.
Understanding the modes of transmission is crucial for implementing effective prevention strategies. AIP’s research and development of infectious diseases encompasses a wide range of conditions, from common illnesses to more severe and potentially life-threatening diseases. Each infectious disease has its unique characteristics, including its incubation period, symptoms, diagnostic methods, and available treatments.
We believe that our advancements in medical research and technology implementing control measures to limit the spread of the disease is a primary goal of public health initiatives worldwide.
The severity of Acute Radiation Syndrome depends on various factors, including the dose of radiation received, the duration of exposure, the type of radiation, and the individual's distance from the radiation source. Our treatment for ARS focuses on managing symptoms and supporting the body's recovery. Prevention is crucial in minimizing the risk of ARS, we aim to provide reliable resources to empower individuals, healthcare professionals, and emergency responders by protecting individuals from the harmful effects of radiation. Together, let's strive to prevent and mitigate the impact of radiation emergencies, ensuring the health and well-being of all.